{"transactions":[{"id":671126,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9730,"price":49.13,"value":478034.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671125,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10350,"price":52.67,"value":545134.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671124,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":40.29,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671123,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.68,"value":1131900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671122,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8750,"price":66.71,"value":583712.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671121,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"price":56.69,"value":1984150.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":28.31,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671120,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5925,"price":85,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":671119,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:02:16.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13300,"price":85,"value":1130500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":5925,"source":{"system":"sec-edgar","filing":"0001628280-26-059907","document":"wk-form4_1788296532.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059907/wk-form4_1788296532.xml","form_type":"4"}},{"id":713602,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T20:30:37.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":40,"value":120000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on  December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share."}],"balance_after":19225,"source":{"system":"sec-edgar","filing":"0001628280-26-047507","document":"wk-form4_1783456224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026047507/wk-form4_1783456224.xml","form_type":"4"}},{"id":730463,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T21:03:33.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":9730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9730,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-044714","document":"wk-form4_1782162210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044714/wk-form4_1782162210.xml","form_type":"4"}},{"id":730462,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T21:03:33.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the\nfirst anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through\nsuch vesting date."}],"balance_after":22225,"source":{"system":"sec-edgar","filing":"0001628280-26-044714","document":"wk-form4_1782162210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044714/wk-form4_1782162210.xml","form_type":"4"}},{"id":843886,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T21:46:09.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":523,"price":36.77,"value":19230.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on  December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.77 per share. The range of sales prices on\nthe transaction date was $36.69 to $36.89 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":16300,"source":{"system":"sec-edgar","filing":"0001628280-26-017797","document":"wk-form4_1773438366.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026017797/wk-form4_1773438366.xml","form_type":"4"}},{"id":843885,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T21:46:09.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":4477,"price":36.08,"value":161530.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on  December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.08 per share. The range of sales prices on\nthe transaction date was $35.65 to $36.53 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":16823,"source":{"system":"sec-edgar","filing":"0001628280-26-017797","document":"wk-form4_1773438366.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026017797/wk-form4_1773438366.xml","form_type":"4"}},{"id":850273,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-03-10T23:03:49.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":15890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027."}],"balance_after":15890,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15890},"source":{"system":"sec-edgar","filing":"0001140361-26-008884","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000114036126008884/form4.xml","form_type":"4"}},{"id":850272,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true}}],"security":"Dividend Equivalent Units","published_at":"2026-03-10T23:03:49.000Z","date":"2026-03-06","kind":"exercise","planned":false,"acquired":false,"shares":1174.4921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1174.4921},"source":{"system":"sec-edgar","filing":"0001140361-26-008884","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000114036126008884/form4.xml","form_type":"4"}},{"id":850271,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2026-03-10T23:03:49.000Z","date":"2026-03-06","kind":"exercise","planned":false,"acquired":false,"shares":23660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":23660},"source":{"system":"sec-edgar","filing":"0001140361-26-008884","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000114036126008884/form4.xml","form_type":"4"}},{"id":850270,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-10T23:03:49.000Z","date":"2026-03-06","kind":"exercise","planned":false,"acquired":true,"shares":1175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan."}],"balance_after":46526,"source":{"system":"sec-edgar","filing":"0001140361-26-008884","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000114036126008884/form4.xml","form_type":"4"}},{"id":850269,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-10T23:03:49.000Z","date":"2026-03-06","kind":"exercise","planned":false,"acquired":true,"shares":23660,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45351,"source":{"system":"sec-edgar","filing":"0001140361-26-008884","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000114036126008884/form4.xml","form_type":"4"}},{"id":1111622,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:30:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":10350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":10350,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0000950170-25-086268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086268/ownership.xml","form_type":"4"}},{"id":1111621,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:30:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":21300,"source":{"system":"sec-edgar","filing":"0000950170-25-086268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086268/ownership.xml","form_type":"4"}},{"id":1214458,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-03-10T22:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":23660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2026."}],"balance_after":23660,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":23660},"source":{"system":"sec-edgar","filing":"0000950170-25-036573","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000095017025036573/ownership.xml","form_type":"4"}},{"id":1221641,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Dividend Equivalent Units","published_at":"2025-03-06T00:00:23.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":423.0127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on June 3, 2024 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on June 3, 2024 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":423.0127},"source":{"system":"sec-edgar","filing":"0000950170-25-034011","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000095017025034011/ownership.xml","form_type":"4"}},{"id":1221640,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-03-06T00:00:23.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":21267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 4, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 4, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":21267},"source":{"system":"sec-edgar","filing":"0000950170-25-034011","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000095017025034011/ownership.xml","form_type":"4"}},{"id":1221639,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-06T00:00:23.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan."}],"balance_after":21691,"source":{"system":"sec-edgar","filing":"0000950170-25-034011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000095017025034011/ownership.xml","form_type":"4"}},{"id":1221638,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-06T00:00:23.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":21267,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21267,"source":{"system":"sec-edgar","filing":"0000950170-25-034011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000095017025034011/ownership.xml","form_type":"4"}},{"id":1483431,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-11T20:21:26.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-24-071930","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071930/ownership.xml","form_type":"4"}},{"id":1483430,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:21:26.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":14400,"source":{"system":"sec-edgar","filing":"0000950170-24-071930","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071930/ownership.xml","form_type":"4"}},{"id":1491405,"issuer":{"id":3277,"kind":"organization","name":"Viatris Inc","symbol":"VTRS"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-04T22:05:08.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":21267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 4, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 4, 2025."}],"balance_after":21267,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":21267},"source":{"system":"sec-edgar","filing":"0000950170-24-068940","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000095017024068940/ownership.xml","form_type":"4"}},{"id":1809519,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:12.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35382,"price":0.75,"value":26536.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":14.17,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":35382},"source":{"system":"sec-edgar","filing":"0001415889-23-012127","document":"form4-08112023_040803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588923012127/form4-08112023_040803.xml","form_type":"4"}},{"id":1809518,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2023-08-11T20:10:12.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12169,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right (\"CVR\") per share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 206 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") for the purchase period from April 3, 2023 to August 3, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right (\"CVR\") per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-23-012127","document":"form4-08112023_040803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588923012127/form4-08112023_040803.xml","form_type":"4"}},{"id":1823965,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-24T23:44:36.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":false,"shares":5528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested."}],"balance_after":12163,"derivative":{"exercise_price":19.24,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":5528},"source":{"system":"sec-edgar","filing":"0001415889-23-011446","document":"form4-07242023_110732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588923011446/form4-07242023_110732.xml","form_type":"4"}},{"id":1823964,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2023-07-24T23:44:36.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":5528,"price":19.24,"value":106358.72,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 786 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") for the purchase periods from October 1, 2021 to March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock . These transaction are exempt under Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."}],"balance_after":11963,"source":{"system":"sec-edgar","filing":"0001415889-23-011446","document":"form4-07242023_110732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588923011446/form4-07242023_110732.xml","form_type":"4"}},{"id":1847823,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:41.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-038824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038824/doc4.xml","form_type":"4"}},{"id":1847822,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T21:00:41.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting the earlier (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001209191-23-038824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038824/doc4.xml","form_type":"4"}},{"id":1860494,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T12:00:14.000Z","date":"2023-06-08","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":22.06,"value":110300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $22.06 per share. The range of actual purchase prices on the transaction date was $22.02 to $22.08 per share. Detailed information on the exact number of shares purchased at each price can be obtained from the issuer upon request."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-23-035618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123035618/doc4.xml","form_type":"4"}},{"id":1982953,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T21:43:45.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":460000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the options are fully vested."}],"balance_after":460000,"derivative":{"exercise_price":1.09,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":460000},"source":{"system":"sec-edgar","filing":"0001415889-23-003682","document":"form4-03012023_090336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588923003682/form4-03012023_090336.xml","form_type":"4"}},{"id":2225437,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T20:47:47.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":8750,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001209191-22-038441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122038441/doc4.xml","form_type":"4"}},{"id":2308267,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-04T23:08:52.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock.  In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the date of grant, subject to continued service as a director through each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock.  In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock.  In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock."}],"balance_after":35000,"derivative":{"exercise_price":28.31,"expiration_date":"2031-12-31","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-22-022681","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122022681/doc4a.xml","form_type":"4/A","original_submission_date":"2022-01-10"}},{"id":2381497,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-22T22:00:47.000Z","date":"2022-02-18","kind":"grant","acquired":true,"shares":230000,"price":1.48,"value":340400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested."}],"balance_after":230000,"derivative":{"exercise_price":1.48,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001415889-22-001636","document":"form4-02222022_050222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588922001636/form4-02222022_050222.xml","form_type":"4"}},{"id":2438924,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-10T21:34:55.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to continued service as a director through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":28.31,"expiration_date":"2031-12-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-002705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122002705/doc4.xml","form_type":"4"}},{"id":2447310,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-04T21:15:20.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":400000,"price":3.03,"value":1212000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 30% on January 3, 2023 and 70% on January 3, 2024."}],"balance_after":400000,"derivative":{"exercise_price":3.03,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001415889-22-000194","document":"form4-01042022_040103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588922000194/form4-01042022_040103.xml","form_type":"4"}},{"id":2522472,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2021-11-05T20:15:44.000Z","date":"2021-11-04","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock units set forth in this table vests as to 20% on the first anniversary of the date of grant, 20% on the second anniversary of the date of grant, and 60% on the third anniversary of the date of grant, subject to the grantee's continued service to the Company on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,239 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") for the purchase period of April 1, 2021 to September 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2021. This transaction is exempt under Rule 16b-3(c)."}],"balance_after":73461,"source":{"system":"sec-edgar","filing":"0001415889-21-005084","document":"form4-11052021_011112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588921005084/form4-11052021_011112.xml","form_type":"4"}},{"id":2858275,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-16T13:00:11.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vest as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested."}],"balance_after":200000,"derivative":{"exercise_price":39.81,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-21-000690","document":"form4-02162021_080201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000141588921000690/form4-02162021_080201.xml","form_type":"4"}},{"id":2949700,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-12-10T23:13:57.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":22222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22222},"source":{"system":"sec-edgar","filing":"0001104659-20-134299","document":"tm2037869-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000110465920134299/tm2037869-1_4.xml","form_type":"4"}},{"id":2949699,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-10T23:13:57.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":22222,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into shares of the Issure's Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock."}],"balance_after":22222,"source":{"system":"sec-edgar","filing":"0001104659-20-134299","document":"tm2037869-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000110465920134299/tm2037869-1_4.xml","form_type":"4"}},{"id":4004845,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T16:42:07.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":56615,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":56615},"source":{"system":"sec-edgar","filing":"0001127602-18-010645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218010645/form4.xml","form_type":"4"}},{"id":4004844,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T16:42:07.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":113230,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":113230},"source":{"system":"sec-edgar","filing":"0001127602-18-010645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218010645/form4.xml","form_type":"4"}},{"id":4004843,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T16:42:07.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":42727,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42727},"source":{"system":"sec-edgar","filing":"0001127602-18-010645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218010645/form4.xml","form_type":"4"}},{"id":4004842,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T16:42:07.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":14230,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14230},"source":{"system":"sec-edgar","filing":"0001127602-18-010645","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218010645/form4.xml","form_type":"4"}},{"id":4004841,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Common Stock","published_at":"2018-03-08T16:42:07.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":5758.0405,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 454.9542 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the \"Merger Agreement\"), between the Company, Sanofi, a French soci?t? anonyme (the \"Parent\"), and Blink Acquisition Corp. (\"Merger Sub\"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\").  Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $105.00 in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-18-010645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218010645/form4.xml","form_type":"4"}},{"id":4054183,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Restricted Stock Units","published_at":"2018-02-15T22:09:20.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":7114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":14230,"derivative":{"underlying":"Common Stock","underlying_shares":7114},"source":{"system":"sec-edgar","filing":"0001127602-18-006425","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218006425/form4.xml","form_type":"4"}},{"id":4054182,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Common Stock","published_at":"2018-02-15T22:09:20.000Z","date":"2018-02-14","kind":"tax_withholding","acquired":false,"shares":2126,"price":103.52,"value":220083.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":5303.0863,"source":{"system":"sec-edgar","filing":"0001127602-18-006425","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218006425/form4.xml","form_type":"4"}},{"id":4054181,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Common Stock","published_at":"2018-02-15T22:09:20.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":7114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 315.0863 shares acquired under the Company's Employee Stock Purchase Plan on April 5, 2017, July 6, 2017, September 29, 2017 and December 29, 2017."}],"balance_after":7429.0863,"source":{"system":"sec-edgar","filing":"0001127602-18-006425","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218006425/form4.xml","form_type":"4"}},{"id":4078461,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Restricted Stock Units","published_at":"2018-02-02T22:13:04.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":42727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."}],"balance_after":42727,"derivative":{"underlying":"Common Stock","underlying_shares":42727},"source":{"system":"sec-edgar","filing":"0001127602-18-003806","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760218003806/form4.xml","form_type":"4"}},{"id":4371268,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T20:26:08.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":113230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in full on the third anniversary of the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":113230,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":113230},"source":{"system":"sec-edgar","filing":"0001127602-17-012946","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760217012946/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4371267,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T20:26:08.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":56615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":56615,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":56615},"source":{"system":"sec-edgar","filing":"0001127602-17-012946","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760217012946/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4441922,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T21:35:04.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":113028,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in full on the third anniversary of the date of grant."}],"balance_after":113028,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":113028},"source":{"system":"sec-edgar","filing":"0001127602-17-006607","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760217006607/form4.xml","form_type":"4"}},{"id":4441921,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T21:35:04.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":56514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in three equal annual installments beginning on February 14, 2018."}],"balance_after":56514,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":56514},"source":{"system":"sec-edgar","filing":"0001127602-17-006607","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760217006607/form4.xml","form_type":"4"}},{"id":4441920,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":17936,"kind":"person","name":"Vivaldi Coelho Rogerio","position":1,"cik":"0001610381","reported_name":"Vivaldi Coelho Rogerio","relationship":{"officer":true,"officer_title":"EVP, Chief Global Therapeutics"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T21:35:04.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":21344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":21344,"derivative":{"underlying":"Common Stock","underlying_shares":21344},"source":{"system":"sec-edgar","filing":"0001127602-17-006607","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610381/000112760217006607/form4.xml","form_type":"4"}}]}